1. Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: a patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials. (3rd October 2022) Authors: Moura, F; Wiviott, S; Chertow, G; Dwyer, J; Gause-Nilsson, I; Johansson, P; Langkilde, A; McMurray, J; Mosenzon, O; Raz, I; Rossing, P; Wheeler, D; Sabatine, M; Heerspink, H Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Influence of cardiovascular drugs on the efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. (14th October 2021) Authors: Oyama, K; Raz, I; Cahn, A; Goodrich, E; Bhatt, D; Leiter, L; McGuire, D; Wilding, J; Gause-Nilsson, I; Mosenzon, O; Sabatine, M; Wiviott, S Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. (15th December 2021) Authors: Sammons, E; Hopewell, J C; Chen, F; Stevens, W; Wallendszus, K; Valdes-Marquez, E; Dayanandan, R; Knott, C; Murphy, K; Wincott, E; Baxter, A; Goodenough, R; Lay, M; Hill, M; Macdonnell, S; Fabbri, G; Lucci, D; Fajardo-Moser, M; Brenner, S; Hao, D Journal: European heart journal Issue: Volume 43:Number 14(2022) Page Start: 1416 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗